ATE405294T1 - Gezielt eingesetzte agenzien zur nervenregeneration - Google Patents
Gezielt eingesetzte agenzien zur nervenregenerationInfo
- Publication number
- ATE405294T1 ATE405294T1 AT03765155T AT03765155T ATE405294T1 AT E405294 T1 ATE405294 T1 AT E405294T1 AT 03765155 T AT03765155 T AT 03765155T AT 03765155 T AT03765155 T AT 03765155T AT E405294 T1 ATE405294 T1 AT E405294T1
- Authority
- AT
- Austria
- Prior art keywords
- nerve regeneration
- targeted agents
- sub
- therapeutic agent
- neuronal cell
- Prior art date
Links
- 210000005036 nerve Anatomy 0.000 title 1
- 230000008929 regeneration Effects 0.000 title 1
- 238000011069 regeneration method Methods 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 210000002569 neuron Anatomy 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0216865.6A GB0216865D0 (en) | 2002-07-19 | 2002-07-19 | Targetted agents for nerve regeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE405294T1 true ATE405294T1 (de) | 2008-09-15 |
Family
ID=9940817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03765155T ATE405294T1 (de) | 2002-07-19 | 2003-07-15 | Gezielt eingesetzte agenzien zur nervenregeneration |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060110409A1 (de) |
| EP (1) | EP1523336B1 (de) |
| JP (1) | JP2005536514A (de) |
| AT (1) | ATE405294T1 (de) |
| AU (1) | AU2003254463B2 (de) |
| CA (1) | CA2492806A1 (de) |
| DE (1) | DE60323099D1 (de) |
| GB (1) | GB0216865D0 (de) |
| WO (1) | WO2004009126A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US7795218B2 (en) * | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
| DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| JP2008515808A (ja) * | 2004-10-04 | 2008-05-15 | トリニティ バイオシステムズ インコーポレーテッド | 針不用の高分子送達のための方法及び組成物 |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| WO2007067596A2 (en) * | 2005-12-05 | 2007-06-14 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of antibodies |
| US20090148401A1 (en) * | 2005-12-05 | 2009-06-11 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
| US20090305978A1 (en) * | 2006-03-16 | 2009-12-10 | Trinity Biosystems, Inc. | Methods for increasing the size of animals using needleless delivery constructs |
| US20090092660A1 (en) * | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
| EP2236516A1 (de) * | 2009-03-31 | 2010-10-06 | Charité-Universitätsmedizin Berlin (Charité) | Polypeptide und deren Verwendung zur Behandlung von traumatischer oder degenerativer Nervenläsion |
| JP2013503198A (ja) | 2009-08-27 | 2013-01-31 | シナプティック リサーチ,リミテッド ライアビリティ カンパニー | 人工多能性幹(iPS)細胞または組織特異的細胞を誘導するための新規タンパク質送達系 |
| US20160051644A1 (en) * | 2013-01-16 | 2016-02-25 | Bal Ram Singh | Botulinum Chimera Compositions for Axonal Regenerative Therapy During Spinal Cord Injury |
| US9868731B2 (en) | 2013-08-22 | 2018-01-16 | Lg Chem, Ltd. | Indole amide compound as inhibitor of necrosis |
| KR20180021703A (ko) * | 2015-05-15 | 2018-03-05 | 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 | 선택된 세포로 분자를 전달하도록 개조된 조작된 클로스트리디움 보툴리눔 독소 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| WO1999008533A1 (en) * | 1997-08-13 | 1999-02-25 | Yale University | Central nervous system axon regeneration |
| GB9824282D0 (en) | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
| CA2392208A1 (en) * | 1999-11-16 | 2001-05-25 | Johanna C. Vanderspek | Fusion proteins that specifically inhibit protein synthesis in neuronal cells |
| CA2392202C (en) * | 1999-12-02 | 2012-02-28 | Microbiological Research Authority | Constructs for delivery of therapeutic agents to neuronal cells |
| CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
-
2002
- 2002-07-19 GB GBGB0216865.6A patent/GB0216865D0/en not_active Ceased
-
2003
- 2003-07-15 WO PCT/GB2003/003082 patent/WO2004009126A1/en not_active Ceased
- 2003-07-15 DE DE60323099T patent/DE60323099D1/de not_active Expired - Fee Related
- 2003-07-15 CA CA002492806A patent/CA2492806A1/en not_active Abandoned
- 2003-07-15 AT AT03765155T patent/ATE405294T1/de not_active IP Right Cessation
- 2003-07-15 JP JP2004522304A patent/JP2005536514A/ja active Pending
- 2003-07-15 AU AU2003254463A patent/AU2003254463B2/en not_active Ceased
- 2003-07-15 US US10/521,401 patent/US20060110409A1/en not_active Abandoned
- 2003-07-15 EP EP03765155A patent/EP1523336B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003254463A1 (en) | 2004-02-09 |
| GB0216865D0 (en) | 2002-08-28 |
| US20060110409A1 (en) | 2006-05-25 |
| AU2003254463B2 (en) | 2008-11-13 |
| EP1523336B1 (de) | 2008-08-20 |
| WO2004009126A1 (en) | 2004-01-29 |
| CA2492806A1 (en) | 2004-01-29 |
| EP1523336A1 (de) | 2005-04-20 |
| JP2005536514A (ja) | 2005-12-02 |
| DE60323099D1 (de) | 2008-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE405294T1 (de) | Gezielt eingesetzte agenzien zur nervenregeneration | |
| CY1107467T1 (el) | Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων | |
| AU1718400A (en) | Method for treating pain | |
| MY134110A (en) | Combinations of reboxetine and neuroleptic agents | |
| ID28916A (id) | Pengobatan ketagihan dan perilaku yang berkaitan dengan ketagihan | |
| BR9915744A (pt) | Derivados 4-arilquinolin-2-ona 3-substituìdos como moduladores do canal de potássio | |
| PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
| WO2004093803A3 (en) | Photochemotherapeutic compounds for use in treatment of pin1-associated states | |
| TR200000755T2 (tr) | Karşıt olma-karşı gelme bozukluğunun tedavisi. | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| WO2005082341A3 (en) | NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF | |
| WO2004066990A3 (en) | Methods of treating lower urinary tract disorders using sodium channel modulators | |
| DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
| DK1234043T3 (da) | Konstruktion for afgivelse af terapeutiske midler til neuroceller | |
| DK0946157T3 (da) | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte | |
| PT1000046E (pt) | Derivados de piperazina activos no trato urinario inferior | |
| BR0115882A (pt) | Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária | |
| BRPI0412694A (pt) | compostos | |
| ES2141330T3 (es) | Monohidrato de (e)-2'-desoxi-2'-(fluorometileno)citidina. | |
| EP1988915A4 (de) | Verfahren zur modulierung der zellaktivität und mittel zur verwendung damit | |
| AU2002347984A1 (en) | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders | |
| NO20005548D0 (no) | Mykobakterieinhibitorer | |
| BR9914722A (pt) | Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool | |
| AU9067198A (en) | Proton pump inhibitor in therapeutic combination with antibacterial substances | |
| DK1239861T3 (da) | Kombinationaf cyamemazin og et atypisk neuroleptikum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |